Industries > Pharma > Next-Generation Cancer Diagnostics Market Forecast 2017-2027

Next-Generation Cancer Diagnostics Market Forecast 2017-2027

Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques

PUBLISHED: 10 May 2017
PAGES: 166
PRODUCT CODE: PHA0192

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

The next-generation cancer diagnostics market is expected to grow at a CAGR of 16.5% in the first half of the forecast period and CAGR of 19.1% in the second half of the forecast period. The market is estimated at $1.9bn in 2016 and $4.1bn in 2021.

While the number of new cancer cases is expected to reach 24 million by 2035, the cost savings that could be achieved with early diagnosis will be the main driver for the market. Advances in molecular biology will also help expand the cancer diagnostics test menu.

Companion cancer diagnostics can be costly but we expect them to be increasingly adopted, particularly when choosing expensive cancer therapies. Laboratory automation, standardised commercial cancer tests and affordable benchtop instruments will continue to reduce the costs of molecular testing.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 166-page report you will receive 87 charts – all unavailable elsewhere.

The 166-page report provides clear detailed insight into the next-generation cancer diagnostics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Next-Generation Cancer Diagnostics Market Forecast 2017-2027

Report Scope
Forecasts and analysis of the next-generation cancer diagnostics market from 2017 to 2027.

• 5 next-generation cancer diagnostics submarkets forecast and analysis from 2017 to 2027:
– Advanced PCR Techniques
– In Situ Hybridization (ISH)
– Circulating Tumour Cells (CTCs) Analysis
– Microarray
– Next-Generation Sequencing (NGS)

• Revenue forecasts for 8 leading national or regional next-generation cancer diagnostics market from 2017 to 2027:
– US
– EU5
– Japan
– China
– India
– Brazil
– Russia
– Rest of the World

• Assessment of selected leading companies marketing next-generation cancer diagnostics, examining recent performance and outlooks:
– Roche Diagnostics
– Abbott Laboratories
– Qiagen
– Thermo Fisher Scientific
– Agilent Technologies
– Hologic
– Illumina
– Myriad Genetics

SWOT analysis of the next-generation cancer diagnostics market, and discusses some current trends.

Visiongain’s study is intended for anyone requiring commercial analyses for the next-generation cancer diagnostics market. You find data, trends and predictions.

Buy our report today Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Next-Generation Cancer Diagnostics Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Next-Generation Cancer Diagnostics Market Forecast 2017-2027


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category